Share Issue News

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5th, 2026, to three non-executive employees of non-qualified stock...

KINSTON, N.C.--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX) (the “Company” or “flyExclusive”), one of the nation’s leading private aviation operators, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 93,000 shares of common stock to three new employees under the Company’s 2024 Indu...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company’s common stock to one new employee (the “In...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,...

HAMILTON, Bermuda--(BUSINESS WIRE)--January 7, 2026-- Triton International Limited (the “Company” or “Triton”) today announced the pricing of an underwritten offering of 7,000,000 of the Company’s 7.500% Series G Cumulative Redeemable Perpetual Preference Shares with a liquidation preference of $25.00 per share (the “Series G Preference Shares”) for gross proceeds of $175,000,000. The Company intends to use the net proceeds from the offering for general corporate purposes, including the purchas...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4)....

FIRESTONE, Colo.--(BUSINESS WIRE)--Rare Element Resources announces intent to launch a rights offering of common shares with proceeds to advance the Bear Lodge Rare Earth Project....

KELOWNA, British Columbia--(BUSINESS WIRE)--Not for Distribution to U.S. Newswire Services or for Dissemination in the United States Kiboko Gold Inc. (TSXV: KIB) (“Kiboko” or the “Company”) announces that, in connection with its non-brokered private placement announced on September 30, 2025 and amended on November 27, 2025 (the “Private Placement”), the Company has reserved the right to increase the size of the Private Placement by up to 20%. As a result, up to an additional 2,500,000 post-cons...

LIMOGES, France--(BUSINESS WIRE)--Regulatory News: Legrand (Paris:LR): Date Total number of shares composing the share capital Total number of voting rights December 31, 2025 262,245,733 Theoretical number of voting rights: 262,245,733 Number of exercisable voting rights*: 261,633,259 (*) After deduction of shares without voting rights The variation of the total number of shares since the latest release of financial statements is reminded below: Total number of shares as at October 31, 2025 262...